Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,382.75
-32.80 (-2.32%)
Official Closing Price
Updated: 7:00 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Anthropic's $1.4 Trillion IPO: The Ultimate Guide
↗
Today 12:20 EST
Both teams see promise in the business, but Team Rule Breakers wants to see a few more quarters of results, while Team Hidden Gems is open to buying.
Via
The Motley Fool
Topics
Artificial Intelligence
Initial Public Offering
Supply Chain
This Magnificent Vanguard ETF Could Turn $500 per Month Into $1 Million in Under 30 Years
↗
Today 8:49 EST
Investors can build life-changing wealth in the stock market with a combination of patience and consistency.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Have $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.
↗
Today 8:20 EST
Even a small share of the massive market for weight loss drugs could lead to a significant increase in this company's share price.
Via
The Motley Fool
Eli Lilly (NYSE:LLY): Strong Growth Paired With a High-Quality Technical Setup
↗
Today 5:31 EST
Via
Chartmill
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
↗
November 17, 2026
Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward.
Via
The Motley Fool
New Analysis Explains What Lilly’s ObesityWeek 2026 EloraTZP Results Add to the September Phase 2b Readout and What They Leave Unchanged
November 17, 2026
Via
Press Release Distribution Service
Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head
↗
November 16, 2026
Eli Lilly’s pipeline is an embarrassment of riches.
Via
The Motley Fool
Better Healthcare ETF: Invesco's PJP vs. Simplify's PINK
↗
November 15, 2026
Concentrated pharma exposure delivered 31% returns over one year, while active healthcare management achieved 18%.
Via
The Motley Fool
Topics
ETFs
Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
↗
November 15, 2026
Hint: It’s not a bad investment idea.
Via
The Motley Fool
Which Healthcare ETF Is the Better Buy: VanEck’s Pharma Fund PPH or iShares’ Biotech Fund IBB?
↗
November 15, 2026
One fund owns the big drugmakers that pay dividends. The other owns the broader biotech field, where stocks swing more. Here is which fits long-term investors.
Via
The Motley Fool
Topics
ETFs
LifeMD: 3 Key Takeaways for Long-Term Investors
↗
November 14, 2026
Lower acquisition costs and flat overhead could let LifeMD keep more of each subscriber's revenue as patient volume grows.
Via
The Motley Fool
Topics
Earnings
Firefly Aerospace vs. Redwire: Which Industrials Stock Is a Better Buy for 2027?
↗
November 14, 2026
Firefly's $1.4 billion backlog and Redwire's 45.8% revenue growth point to very different bets, and the valuation gap may be the deciding factor.
Via
The Motley Fool
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
↗
November 13, 2026
Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.
Via
The Motley Fool
What LifeMD (LFMD) Said on Its Q3 Earnings Call
↗
November 12, 2026
LifeMD (NASDAQ:LFMD) lowered its full-year revenue and adjusted EBITDA outlook after third-quarter sales fell short of its forecast, as the virtual healthcare company cut marketing spending and took...
Via
MarketBeat
Topics
Earnings
Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It
↗
November 12, 2026
The world's largest healthcare company is making shrewd investments in its future.
Via
The Motley Fool
Topics
Artificial Intelligence
More Good News for Eli Lilly Sends the Stock Even Higher
↗
November 12, 2026
Lilly's experimental GLP-1 is effective in treating osteoarthritic knee pain.
Via
The Motley Fool
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
↗
November 12, 2026
Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.
Via
MarketBeat
Topics
Earnings
Lawsuit
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
↗
November 11, 2026
Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.
Via
The Motley Fool
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?
↗
November 11, 2026
These drugmakers offer very different risk-reward profiles.
Via
The Motley Fool
S&P 500 After-Hours Movers: MNST, RDDT Among Gainers; VEEV, LLY Among Losers in Latest Session
↗
November 11, 2026
Via
Chartmill
Topics
Stocks
Which Is the Better Buy: iShares’ Pharma ETF IHE or First Trust’s Biotech Fund FBT?
↗
November 11, 2026
iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.
Via
The Motley Fool
Topics
Derivatives
ETFs
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?
↗
November 11, 2026
Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.
Via
The Motley Fool
A Billionaire Investor Links Cancer Treatment and Wireless Technology as AI Pharmaceutical Testing Gains Ground
November 11, 2026
Via
AB Newswire
Topics
Artificial Intelligence
My Forever Portfolio: 4 Spectacular Stocks You Can Buy Now and Never Sell
↗
November 11, 2026
It takes a slightly different mindset when you're investing for a longer time horizon.
Via
The Motley Fool
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?
↗
November 10, 2026
These stocks have been going in different directions over the past year, but that trend may not necessarily continue.
Via
The Motley Fool
Hims & Hers: 3 Key Takeaways for Long-Term Investors
↗
November 10, 2026
Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.
Via
The Motley Fool
Topics
Earnings
This Growth ETF Has Crushed the S&P 500 Since 2004. Here's Why It's Still a Buy.
↗
November 10, 2026
The upside outweighs the inevitable volatility.
Via
The Motley Fool
Topics
ETFs
Stocks
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
↗
November 10, 2026
The healthcare stock has soared past the S&P 500 this year as its results have been strong in recent quarters.
Via
The Motley Fool
Topics
Stocks
Want to Escape the AI Sell-Off? This ETF Offers a Surprising Alternative
↗
November 09, 2026
As tech stocks sell off, the ProShares S&P 500 ex-Technology ETF (SPXT) offers reduced AI exposure, but its mega-cap holdings, light liquidity, and trailing returns temper its appeal.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Stocks
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
November 09, 2026
From
Gabelli Funds
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.